PET in Uterine Malignancies (Report‪)‬

1. INTRODUCTION Positron Emission Tomography (PET) or integrated PET/Computed Tomography (PET/CT) with [sup.18]F-FluoroDeoxy-Glucose ([sup.18]F-FDG) study is a functional, non invasive whole body examination, that allows to metabolically characterize undetermined morphological findings, stage/re-stage disease, evaluate treatment response and monitor the therapy in a large number of malignancies (lymphomas, lung, breast, colon-rectal cancer, etc). In the genital tract of women the use of PET is controversial and it is limited by the urinary excretion of the [sup.18]F-FDG, that interfere with the evaluation of uterus and vagina, and by the numerous false positive findings related to the presence of physiological tracer uptakes in the bowel, ovaries, and in the uterus itself. However, the clinical introduction of integrated PET/CT tomography, allowing the co-registration and the superimposition of anatomical and functional images and thus the exact localization of all the [sup.18]F-FDG uptakes, improved PET diagnostic accuracy [1].